Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Current Deferred Revenue (2016 - 2017)

Historic Current Deferred Revenue for Coherus Oncology (CHRS) over the last 5 years, with Q1 2017 value amounting to $669000.0.

  • Coherus Oncology's Current Deferred Revenue fell 9865.21% to $669000.0 in Q1 2017 from the same period last year, while for Mar 2017 it was $669000.0, marking a year-over-year decrease of 9865.21%. This contributed to the annual value of $892000.0 for FY2016, which is 9820.24% down from last year.
  • Per Coherus Oncology's latest filing, its Current Deferred Revenue stood at $669000.0 for Q1 2017, which was down 9865.21% from $892000.0 recorded in Q4 2016.
  • Over the past 5 years, Coherus Oncology's Current Deferred Revenue peaked at $61.3 million during Q2 2016, and registered a low of $669000.0 during Q1 2017.
  • In the last 5 years, Coherus Oncology's Current Deferred Revenue had a median value of $24.0 million in 2014 and averaged $25.7 million.
  • In the last 5 years, Coherus Oncology's Current Deferred Revenue skyrocketed by 11768.86% in 2016 and then plummeted by 9865.21% in 2017.
  • Quarter analysis of 5 years shows Coherus Oncology's Current Deferred Revenue stood at $14.3 million in 2013, then soared by 59.63% to $22.8 million in 2014, then skyrocketed by 117.64% to $49.6 million in 2015, then crashed by 98.2% to $892000.0 in 2016, then dropped by 25.0% to $669000.0 in 2017.
  • Its last three reported values are $669000.0 in Q1 2017, $892000.0 for Q4 2016, and $1.4 million during Q3 2016.